Author/Editor		Mali, Polona; Kitanovski, Lidija; Jazbec, Janez; Anžič, Jožica; Benedik-Dolničar, Majda
Title		Naše izkušnje pri zdravljenju anemije z eritropoietinom pri otroku z rakom
Translated title		Erythropoietin treatment for anemia in children with cancer - single centre experiences
Type		članek
Source		Zdrav Vestn
Vol. and No.		Letnik 73, št. Suppl 1
Publication year		2004
Volume		str. I-43-6
Language		slo
Abstract		Background. Anemia, a common complication during treatment of malignant disease in children, was frequently treated with red blood cell transfusions. Several studies have shown, that the introduction of recombinant human erythropoietin (rh EPO) for treating anemia in patients has been effective in reducing the need for transfusions. Variable doses of EPO from 150 to 900 1U/kg body weight have been used usually three times weekly. Recently some studies showed equally effective once weekly administration of EPO with proposed doses for children of 450 to 600 IU/ kg body weight. Efficacy and safety of once weekly EPO therapy was tested in 8/10 children treated in our Unit for solid tumors and nonHodgkin's lymphoma. In this article we would like to present our one year experience with EPO treatment. Patients and methods. Patients have subcutaneously received the EPO dose of 600 UI/kg body weight once weekly. Hemoglobin response and transfusion needs before and during treatment with EPO were analyzed. Results. Response was seen in 7/8 of patient, with increased hemoglobin level and lower transfusion needs. Only one patient was poor responder at first, but responded perfect after twice weekly EPO application. No adverse reaction related to EPO therapy was observed. Condusions. Our experience with treating anemia in pediatric cancer patients who undergo intensive and aggressive chemotherapy treatment regimens are good and promising. Once weekly dosage regimen is child friendly and acceptable way of treating anemia.
Summary		Izhodišča. Zdravljenje anemije, pogostega zapleta med zdravljenjem raka pri otrocih, je do sedaj potekalo s transfuzijami koncentriranih eritrocitov. Številne raziskave po svetu poročajo o uspešni in varni uporabi rekombinantnega človeškega eritropoietina (EPO), ki pomembno zmanjša potrebo po transfuzijah. Odmerki EPO so različni, od 150 do 900 enot/kg telesne teže trikrat na teden. V zadnjem času je vse več poročil o enaki uspešnosti enkrat tedenskega odmerjanja, predlagani odmerki za otroke so od 450 do 600 enot/kg telesne teže. Uspešnost in varnost enkrat tedenskega odmerka EPO smo ocenjevali pri 8/10 naših bolnikov, ki smo jih zdravili s citostatiki zaradi solidnih tumorjev in neHodgkinovega limfoma. V prispevku želimo predstaviti naše enoletne izkušnje pri tem načinu zdravljenja anemije. Bolniki in metode. Bolniki so prejemali EPO podkožno v odmerku 600 enot/kg telesne teže enkrat na teden. Redno smo spremljali vrednosti hemaglobina in beležili potrebe po transfuzijah koncentriranih eritrocitov pred zdravljenjem z EPO in med njim. Rezultati. Pri 7/8 bolnikov smo ugotavljali ugoden odziv na EPO s postopnim povečevanjem koncentracije hemoglobina in zmanjšanjem potreb po transfuzijah koncentriranih eritrocitov. Pri 1 bolnici, ki je bila slabo odzivna na enkrattedenski odmerek EPO, smo ugoden odziv s povečanjem koncentracije hemoglobina dosegli po uvedbi dvakrattedenskega odmerka. Za EPO opisanih neželenih učinkov med zdravljenjem nismo ugotovili. Zaključki. Naše izkušnje z EPO za zdravljenje anemije po intenzivnem zdravljenju s citostatiki sa ugodne. Enkrattedensko dajanje EPO je otroku zelo prijazen in sprejemljiv način zdravljenja anemije.
Descriptors		NEOPLASMS ANEMIA ERYTHROPOIETIN, RECOMBINANT CHILD HEMOGLOBINS ERYTHROCYTE TRANSFUSION TREATMENT OUTCOME